Article
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy - 1 Dec 2004
Andries Koen, Azijn Hilde, Thielemans Theo, Ludovici Donald, Kukla Michael, Heeres Jan, Janssen Paul, De Corte Bart, Vingerhoets Johan, Pauwels Rudi, de Béthune Marie-Pierre
Abstract excerpt
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1); however, currently marketed NNRTIs rapidly select resistant virus, and cross-resistance within the class is extensive. A parallel screening strategy was applied to test candidates from a series of diarylpyrimidines against wild-type and resistant HIV strains carrying clinically relevant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.